Literature DB >> 20864634

Comparison of KRAS mutation analysis and FISH for detecting pancreatobiliary tract cancer in cytology specimens collected during endoscopic retrograde cholangiopancreatography.

Benjamin R Kipp1, Emily G Barr Fritcher, Amy C Clayton, Gregory J Gores, Lewis R Roberts, Jun Zhang, Michael J Levy, Kevin C Halling.   

Abstract

Pancreatobiliary tract strictures result either from malignancies of the biliary tract and pancreas or from nonmalignant etiopathogenesis. The goal of this study was to determine whether KRAS mutations could be identified in residual pancreatobiliary stricture brushings and to compare the performance characteristics of KRAS mutation analysis to cytology and fluorescence in situ hybridization (FISH) for the detection of carcinoma. Residual brushing cytology cell pellets were retrieved from 132 patients with subsequent clinicopathologic follow-up of cholangiocarcinoma (n = 41), pancreatic adenocarcinoma (n = 35), gallbladder cancer (n = 2), and nonmalignant strictures (n = 54). All specimens had a prior cytology and FISH UroVysion results as part of clinical practice. KRAS mutation analysis was performed using the quantitative PCR DxS KRAS Mutation Test Kit. KRAS mutation analysis was successful in 130 of 132 specimens. KRAS mutations and polysomic (ie, positive) FISH results were identified in 24 (69%) and 22 (63%) pancreatic adenocarcinoma specimens, respectively, with a combined sensitivity of 86% (30/35). KRAS mutations and polysomic FISH results were identified in 12 (29%) and 17 (41%) cholangiocarcinoma specimens, with a combined sensitivity of 54% (22/41). KRAS mutations were identified in two patients with primary sclerosing cholangitis, and benign follow-up. Residual cytology specimens can be used to detect KRAS mutations by quantitative PCR. Combined KRAS mutation and FISH analysis appear to increase the cancer detection rate in patients with pancreatobiliary strictures.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20864634      PMCID: PMC2963905          DOI: 10.2353/jmoldx.2010.100016

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  30 in total

1.  A comparison of routine cytology and fluorescence in situ hybridization for the detection of malignant bile duct strictures.

Authors:  Benjamin R Kipp; Linda M Stadheim; Shari A Halling; Nicole L Pochron; Scott Harmsen; David M Nagorney; Thomas J Sebo; Terry M Therneau; Gregory J Gores; Piet C de Groen; Todd H Baron; Michael J Levy; Kevin C Halling; Lewis R Roberts
Journal:  Am J Gastroenterol       Date:  2004-09       Impact factor: 10.864

2.  Advanced cytologic techniques for the detection of malignant pancreatobiliary strictures.

Authors:  Laura E Moreno Luna; Benjamin Kipp; Kevin C Halling; Thomas J Sebo; Walter K Kremers; Lewis R Roberts; Emily G Barr Fritcher; Michael J Levy; Gregory J Gores
Journal:  Gastroenterology       Date:  2006-08-16       Impact factor: 22.682

3.  Frequency of K-ras mutations in pancreatic intraductal neoplasias associated with pancreatic ductal adenocarcinoma and chronic pancreatitis: a meta-analysis.

Authors:  Matthias Löhr; Günter Klöppel; Patrick Maisonneuve; Albert B Lowenfels; Jutta Lüttges
Journal:  Neoplasia       Date:  2005-01       Impact factor: 5.715

4.  DNA image analysis combined with routine cytology improves diagnostic sensitivity of common bile duct brushing.

Authors:  S Krishnamurthy; R L Katz; A Shumate; K Strohlein; A Khanna; S L Tucker; I Raijman; S Lahoti
Journal:  Cancer       Date:  2001-06-25       Impact factor: 6.860

5.  Clinical value of K-ras codon 12 analysis and endobiliary brush cytology for the diagnosis of malignant extrahepatic bile duct stenosis.

Authors:  P D Sturm; E A Rauws; R H Hruban; E Caspers; T B Ramsoekh; K Huibregtse; L A Noorduyn; G J Offerhaus
Journal:  Clin Cancer Res       Date:  1999-03       Impact factor: 12.531

6.  Comparison of the novel quantitative ARMS assay and an enriched PCR-ASO assay for K-ras mutations with conventional cytology on endobiliary brush cytology from 312 consecutive extrahepatic biliary stenoses.

Authors:  N T van Heek; S J Clayton; P D J Sturm; J Walker; D J Gouma; L A Noorduyn; G J A Offerhaus; J C Fox
Journal:  J Clin Pathol       Date:  2005-12       Impact factor: 3.411

7.  K-ras mutations in the bile of patients with primary sclerosing cholangitis.

Authors:  S Kubicka; F Kühnel; P Flemming; B Hain; N Kezmic; K L Rudolph; M Manns; P N Meier
Journal:  Gut       Date:  2001-03       Impact factor: 23.059

Review 8.  Serum and bile markers for cholangiocarcinoma.

Authors:  Oliver Nehls; Michael Gregor; Bodo Klump
Journal:  Semin Liver Dis       Date:  2004-05       Impact factor: 6.115

9.  Promoter methylation profiles of tumor suppressor genes in intrahepatic and extrahepatic cholangiocarcinoma.

Authors:  Bin Yang; Michael G House; Mingzhou Guo; James G Herman; Douglas P Clark
Journal:  Mod Pathol       Date:  2005-03       Impact factor: 7.842

10.  A prospective comparison of digital image analysis and routine cytology for the identification of malignancy in biliary tract strictures.

Authors:  Todd H Baron; Gavin C Harewood; Ashwin Rumalla; Nicole L Pochron; Linda M Stadheim; Gregory J Gores; Terry M Therneau; Piet C De Groen; Thomas J Sebo; Diva R Salomao; Benjamin R Kipp
Journal:  Clin Gastroenterol Hepatol       Date:  2004-03       Impact factor: 11.382

View more
  20 in total

Review 1.  Advances in biomarker research for pancreatic cancer.

Authors:  Kruttika Bhat; Fengfei Wang; Qingyong Ma; Qinyu Li; Sanku Mallik; Tze-Chen Hsieh; Erxi Wu
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

2.  Utilization of ancillary studies in the cytologic diagnosis of biliary and pancreatic lesions: the Papanicolaou Society of Cytopathology guidelines for pancreatobiliary cytology.

Authors:  Lester J Layfield; Hormoz Ehya; Armando C Filie; Ralph H Hruban; Nirag Jhala; Loren Joseph; Philippe Vielh; Martha B Pitman
Journal:  Diagn Cytopathol       Date:  2014-04       Impact factor: 1.582

Review 3.  Diagnostic and therapeutic biomarkers in pancreaticobiliary malignancy.

Authors:  Domenico Viterbo; Valerie Gausman; Tamas Gonda
Journal:  World J Gastrointest Endosc       Date:  2016-02-10

4.  Ras in cancer and developmental diseases.

Authors:  Alberto Fernández-Medarde; Eugenio Santos
Journal:  Genes Cancer       Date:  2011-03

5.  Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors.

Authors:  Jesper B Andersen; Bart Spee; Boris R Blechacz; Itzhak Avital; Mina Komuta; Andrew Barbour; Elizabeth A Conner; Matthew C Gillen; Tania Roskams; Lewis R Roberts; Valentina M Factor; Snorri S Thorgeirsson
Journal:  Gastroenterology       Date:  2011-12-13       Impact factor: 22.682

6.  Screening for hepatocellular carcinoma and cholangiocarcinoma: Can biomarkers replace imaging?

Authors:  Maria E Lozada; Roongruedee Chaiteerakij; Lewis R Roberts
Journal:  Curr Hepatol Rep       Date:  2015-06

7.  Detection of IGF2BP3, HOXB7, and NEK2 mRNA expression in brush cytology specimens as a new diagnostic tool in patients with biliary strictures.

Authors:  Hans Dieter Nischalke; Volker Schmitz; Carolin Luda; Katharina Aldenhoff; Cordula Berger; Georg Feldmann; Tilman Sauerbruch; Ulrich Spengler; Jacob Nattermann
Journal:  PLoS One       Date:  2012-08-07       Impact factor: 3.240

Review 8.  Brush Cytology, Forceps Biopsy, or Endoscopic Ultrasound-Guided Sampling for Diagnosis of Bile Duct Cancer: A Meta-Analysis.

Authors:  Seung Bae Yoon; Sung-Hoon Moon; Sung Woo Ko; Hyun Lim; Ho Suk Kang; Jong Hyeok Kim
Journal:  Dig Dis Sci       Date:  2021-07-14       Impact factor: 3.487

Review 9.  An Omics Perspective on Molecular Biomarkers for Diagnosis, Prognosis, and Therapeutics of Cholangiocarcinoma.

Authors:  Pattaya Seeree; Phorutai Pearngam; Supeecha Kumkate; Tavan Janvilisri
Journal:  Int J Genomics       Date:  2015-09-02       Impact factor: 2.326

10.  S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma.

Authors:  A B El-Khoueiry; C Rankin; A B Siegel; S Iqbal; I-Y Gong; K C Micetich; O R Kayaleh; H-J Lenz; C D Blanke
Journal:  Br J Cancer       Date:  2014-01-14       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.